학술논문
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
Document Type
Article
Author
Source
Subject
Language
ISSN
1444-0903
Abstract
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real‐world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)‐resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib‐pretreated cohort. [ABSTRACT FROM AUTHOR]